Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBRT plus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
ChiCTR2300070746Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: progression-free survival. Started Jul 2020; status: recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300070746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070746.